Screener
Bio-Rad Laboratories BIO Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Finance Leases | ||
| Property, plant and equipment, gross | $11.5 | $11.5 |
| Less: accumulated depreciation and amortization | (6.4) | (6.4) |
| Property, plant and equipment, net | $5.1 | $5.1 |
| Current maturities of long-term debt and notes payable | $0.5 | $0.5 |
| Long-term debt, net of current maturities | 8.6 | 8.7 |
| Total finance lease liabilities | $9.1 | $9.2 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's finance lease liabilities?
- Bio-Rad Laboratories (BIO) reported finance lease liabilities of $8.6M in Q1 2026.
- How has Bio-Rad Laboratories's finance lease liabilities changed year-over-year?
- Bio-Rad Laboratories's finance lease liabilities decreased by 4.4% year-over-year, from $9M to $8.6M.
- What is the long-term trend for Bio-Rad Laboratories's finance lease liabilities?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's finance lease liabilities has grown at a -4.6% compound annual growth rate (CAGR), from $11M to $8.7M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.
Ask your AI about Bio-Rad Laboratories's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude